About
Cadex Genomics develops a blood-based assay called Alibrex that enables real-time monitoring of therapy effectiveness by measuring circulating tumor DNA changes in stage IV solid tumor cancer patients, providing results within 12 days after treatment initiation.
Explore Cadex Genomics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.